Analyst Price Target is C$7.26
▲ +93.73% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Canopy Growth in the last 3 months. The average price target is C$7.26, with a high forecast of C$22.00 and a low forecast of C$2.50. The average price target represents a 93.73% upside from the last price of C$3.75.
Current Consensus is
The current consensus among 13 contributing investment analysts is to hold stock in Canopy Growth. This rating has held steady since April 2021, when it changed from a Sell consensus rating.
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada to investigate the efficacy of cannabinoids for the treatment of post-concussion neurological diseases in former NHL players; and partnership with Parent Action on Drugs. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.